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Abstract Treatment with kampo, the Japanese traditional
medicine, is a form of pharmacological therapy that com-
bines modern Western and traditional Asian medical
practices. In Japan, various traditional medicines are often
combined with Western medicines and prescribed for
patients with diseases such as gastroesophageal reflux
disease, functional dyspepsia, chronic gastritis, irritable
bowel syndrome, and post-operative ileus. Based on
numerous past observations, Japanese traditional medicines
are thought to be particularly useful in the treatment of
medically unexplained physical symptoms such as nausea,
abdominal discomfort, and anorexia. However, the detailed
mechanism by which they mediate their pharmacological
action is yet unknown. In addition, the clinical evidence to
support their use is insufficient. This review focuses on the
basic evidence of the pharmacological action and the
clinical efficacies of kampo medicines accumulated over
several past decades. In addition, we introduce both the
current novel insights into kampo medicines and the ther-
apeutic approach employed when they are used to treat
various disorders of the gastrointestinal tract.
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Introduction
The Japanese traditional herbal medicine, kampo, is a form of
pharmacological therapy that originated in medieval China
and was developed further in Japan. Treatment with kampo
means a possibility for combination therapy with modern
Western and traditional Asian medical practices. Most such
traditional medicines include various components, and they
are often prescribed for patients with medically unexplained
physical symptoms. However, the detailed mechanism(s) of
the pharmacological action of kampo medicines is yet
unknown. Consequently, a standardized educational system
of these medicines has not been fully established until
recently for medical students or trainees. In other words, the
Japanese Ministry of Health and Welfare has approved the
use of many kampo medicines as ethical medicines based on
the symptoms of the respective patients. Therefore, thera-
peutic strategies that use kampo medicines based on proven
evidence have yet to be established. Hence, kampo therapy is
referred to as experience-based medicine and not evidence-
based medicine, even though these medicines are prescribed
in most clinical fields in Japan. However, extensive evidence
for the clinical efficacies or pharmacological mecha-
nism(s) of kampo medicines has gradually accumulated over
past decades. This review focuses on the basic and clinical
evidence for efficacies of kampo medicines in treating vari-
ous disorders of the gastrointestinal tract (GI) tract and
introduces the current novel insights in this field (Figs. 1, 2).
Gastroesophageal reflux disease (GERD) associated with
esophageal motor function and visceral hypersensitivity
Recently, an increase in the prevalence of GERD has been
reported in Japan and in Western countries owing to factors
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such as obesity associated with the intake of Western food,
a decrease in the Helicobacter pylori infection rate, and
increased prevalence of H. pylori eradication therapy
[1–4]. The primary pathophysiology of GERD is the reflux
of gastric contents, including gastric acid [5]. Esophageal
motor dysfunctions such as an increase in transient lower
esophageal sphincter relaxation (TLESR) are also associ-
ated with the occurrence of GERD [6]. Other factors
contributing to the pathophysiology of GERD include
esophageal peristalsis, mucosal hypersensitivity at the
bottom of the esophagus to reflux contents such as gastric
acid or bile acid, or disorders of gastric motility (gastric
reservoir function or emptying). Hence, the inhibition of
acid secretion by using proton pump inhibitors (PPIs) has
been suggested as the most effective therapeutic strategy
for GERD [7]. However, certain agents that regulate the
physiological functions of the esophagus, e.g., its motor
functions, may also prove useful in GERD treatment.
The Japanese traditional medicine rikkunshito has eight
constituents, viz., Glycyrrhizae radix (4.7 %), Zingiberis
rhizoma (2.3 %), Atractylodis lanceae rhizoma (18.6 %),
Zizyphi fructus (9.3 %), Aurantii nobilis pericarpium
(9.3 %), Ginseng radix (18.6 %), Pinelliae tuber (18.6 %),
and Hoelen (18.6 %) [8], and is widely prescribed for
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patients with upper GI symptoms. Basic studies show that
rikkunshito exhibits a pharmacological action similar to
that of prokinetic agents, as shown by its attenuation of
gastric dysmotility induced by a nitric oxide-synthesizing
enzyme inhibitor [9, 10]. In addition, rikkunshito improves
the delay of gastric emptying mediated by serotonin (5-HT)
type 3 receptor but not dopamine receptors [11]. Con-
versely, rikkunshito increases plasma ghrelin levels, and
regulates motility at the esophagogastric junction [12, 13].
Ghrelin is known to have a strong orexigenic effect [14, 15]
and enhances GI motility [16–18]. Nahata et al. [19]
showed impairment of GI motility in a rat GERD model via
dysfunction of ghrelin signaling and that rikkunshito
restored GI motility by improving the ghrelin response.
These data indicate the possible efficacy of rikkunshito in
the treatment of GERD owing to its pharmacological action
on motor functions throughout the upper GI tract.
Kawahara et al. [20] reported that rikkunshito improved
nausea symptoms in children with GERD by increasing
esophageal clearance and decreasing esophageal acid
exposure time for the esophagus from a 24-h pH moni-
toring study. Rikkunshito is also effective for the relief of
reflux symptoms such as heartburn and acid regurgitation
[21]. Acid secretion inhibitors such as PPIs are the first-
choice agents for GERD treatment; however, we often
encounter PPI-refractory GERD adult patients. Thus, ant-
acid agents may not always be effective for GERD, espe-
cially in the case of a patient with no erosions on the
esophageal mucosa (non-erosive reflux disease: [NERD]).
In our recent report of a randomized, parallel comparative
study of PPI-refractory GERD patients, we stated that ri-
kkunshito combined with standard-dose rabeprazole ther-
apy shows clinical efficacy similar to that of double-dose
PPI [22]. In subgroup analyses of this study, the effec-
tiveness of rikkunshito was more pronounced in male
NERD patients, particularly leptosomatic NERD patients
[22]. By using a rat reflux esophagitis model, Miwa et al.
[23] showed that rikkunshito improves acid regurgitation-
associated circumstances by promoting tight junction pro-
tein formation and suppressing the dilation of intercellular
spaces in the epithelial mucosa. In addition to gastric acid
reflux, bile acid reflux to the bottom part of the esophagus
may also be an important factor in the pathogenesis of
mucosal hypersensitivity leading to PPI-refractory GERD.
Recently, Araki et al. [24] showed that rikkunshito exhibits
potent and differential absorption of bile salts. Correc-
tively, these findings suggest that rikkunshito may have the
potential for improving hypersensitivity to gastric acid or
bile acid at the bottom part of the esophagus. These
pharmacological functions of rikkunshito different from
motor function may suggest other explanations why it
relieves the symptoms of PPI-refractory GERD patients,
especially for NERD. Currently, double-dose PPI and
long-term maintenance therapy is the standard therapeutic
strategy for such PPI-refractory GERD patients [25];
however, a new regimen that includes rikkunshito should
be considered for GERD patients including PPI-refractory
cases.
Mucosal injuries and histological gastritis
(H. pylori-induced gastritis)
Acute inflammation of the stomach is often caused by
factors such as non-steroidal anti-inflammatory drugs
(NSAIDs), ethanol, systemic stress, or H. pylori infection,
all of which may cause mucosal injuries [26–28]. Acid
secretion inhibitors, such as PPIs and histamine type 2
receptor antagonists (H2RAs), or mucoprotective agents,
such as rebamipide and teprenone, are effective for treating
mucosal injuries [29, 30]. Aside from these drugs, some
traditional medicines are also used to protect against acute
gastric injuries. Kase et al. [31] reported that hangesha-
shinto and shosaikoto inhibited ethanol-induced gastric
mucosal injuries in a dose-dependent manner by eliminat-
ing oxygen radicals. Hangeshashinto is also reported to
elevate secretion of mucin, which protects against acute
gastric mucosal injuries. Hangeshashinto improves muco-
sal injuries caused by water-immersion stress and an acute
mucosal injury model; however, shosaikoto did not show
this property. This disparity in their effects may be due to
differences in the respective components of these medi-
cines. Furthermore, rikkunshito exerts a protective effect
against gastric mucosal injuries induced by ethanol. The
effect of rikkunshito is mediated by the inhibition of
decrease in mucin content of the gastric mucosa [32], and
this effect is in part mediated by nitric oxide (NO) but not
prostaglandins or sulfhydryls [33]. Thus, these findings
suggest that both hangeshashinto and rikkunshito exert
protective effects against acute mucosal injuries in the
stomach of rats.
Chronic gastritis, which is characterized by chronic
infiltration of inflammatory cells, hypertrophy or atrophy of
the gastric glands, or intestinal metaplasia, has been proved
to be caused by persistent H. pylori infection. Therefore,
chronic gastritis is also referred to as histological gastritis,
the standard treatment for which includes triple antimi-
crobial therapy. However, some traditional herbal medi-
cines have shown evidence of antimicrobial efficacy
against H. pylori. Ishii reported that 104 of 109 kinds of
medicinal plants and 28 types of spices had anti-H. pylori
activities [34]. Among all crude drugs, gosyuyu had a
markedly higher antibacterial activity against H. pylori
in vitro. Gosyuyuto has four constituents; Evodia fructus,
Zizyphi fructus, Zingiberis rhizoma, and Ginseng radix. In
a clinical study report, Higuchi et al. [35] reported that
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gosyuyuto combined with omeprazole and amoxicillin
yields a higher eradication rate (84 %) than dual therapy
(59 %) without causing any significant adverse effect.
Moreover, Hamasaki et al. [36] analyzed the components
of gosyuyuto and reported that two quinolone compounds
(AM quinolones), 1-methyl-2-[(Z)-8-tridecenyl]-4-(1H)-
quinolone and 1-methyl-2-[(Z)-7-tridecenyl]-4-(1H)-quin-
olone, which were purified from the Evodia fructus have
strong and selective antibacterial activity against the ref-
erence strains and isolated strains of H. pylori from clinical
patients. Further, in vitro studies revealed that the anti-
bacterial effect of these two AM quinolones against
H. pylori is mediated by the inhibition of respiration and
not DNA synthesis, and in vivo studies revealed that they
significantly decreased the number of viable H. pylori in
the stomachs of H. pylori-infected Mongolian gerbils and
reduced neutrophil infiltration without causing harmful
adverse events, including animal mortality [37]. The agents
with a unique antimicrobial mechanism(s) mediated by the
inhibition of bacterial respiration, i.e., mechanisms differ-
ent from that of antibiotics such as amoxicillin, clarithro-
mycin, or metronidazole, may be beneficial for the
improvement of H. pylori-associated gastric diseases,
whether they are used alone or in combination with the
above mentioned antibiotics and PPIs. Thus, there are some
candidates among traditional medicines to treat or protect
against gastric mucosal injuries caused by the above vari-
ous mechanism(s), including H. pylori infection.
Functional dyspepsia (FD)
Another form of chronic gastritis in Japan is a symptomatic
gastritis called functional dyspepsia (FD), and it is classi-
fied as a functional GI disorder (FGID). According to the
Rome III criteria published in 2006 [38], the diagnosis of
FGIDs is based on the following conditions: patients
exhibit symptoms originating from the GI tract without
evident organic disease, and these bothersome symptoms
persist even after various treatments, thus decreasing their
quality of life (QOL) [39]. FD has four representative
symptoms, viz., epigastric pain, epigastric burning, post-
prandial fullness, or early satiety. It is common worldwide,
and its prevalence has increased recently. The pathophys-
iology of FD is characterized by multifunctional disorders
of the upper GI tract, e.g., disorders of GI motility [40],
abnormal acid secretion [41], visceral hypersensitivity
[42], H. pylori infection [43], psychological factors [44,
45], and imbalance of the autonomic nervous system
(ANS) [46]. Of these factors, most studies mainly focus on
the disorders of GI motility, because they are closely
related to the pathogenesis of FD. In general, gastric
motility consists of three phases: reservoir, churning, and
emptying. While previous reports have mainly focused on
the delay in gastric emptying [47], it is necessary to con-
sider the total coordination of these phases for the better
understanding of FD. Gastric accommodation, a reservoir
function, originates from the proximal stomach and is
important for the physiological function of the stomach.
Neurological transmitters such as NO that are essential for
this function have already been elucidated [48, 49].
Impairment of gastric accommodation has also been
reported to cause clinical symptoms such as epigastric
discomfort, early satiety, and bloating of FD patients [50].
Furthermore, we have previously reported that the
impairment of reservoir function is associated with delay in
gastric emptying, which results in dyspeptic symptoms
[40]. Thus, drugs that can improve the impairment of res-
ervoir function of the stomach are desirable. With regard to
traditional medicines, the kampo medicine rikkunshito
regulates GI motility in a manner similar to prokinetic
drugs. Hayakawa et al. [9] reported that, in isolated guinea
pig stomachs, rikkunshito promotes adaptive relaxation,
which means gastric accommodation. Rikkunshito also
induces the relaxation of gastric fundus smooth muscles
isolated from diabetic neuropathic rats with gastric
dysmotility [51]. In addition, rikkunshito can improve
gastric dysmotility mediated by NO or 5-HT3 receptor
pathways [10, 11]. Considering this basic evidence, ri-
kkunshito may be a promising drug for the treatment of FD
in the clinical field.
Unfortunately, an appropriate treatment regimen for FD
has not yet been established, even though a variety of
clinical trials considering the above pathogenesis have
been conducted in Japan. Therefore, treatment may be
empirically adopted for FD patients based on the pre-
dominantly suspected pathogenesis related to respective
symptoms of FD. There is some evidence for the effec-
tiveness of kampo medicines in the treatment of FD under
such conditions. When FD was still called non-ulcer dys-
pepsia (NUD), Tatsuta et al. [52] illustrated the efficacy of
rikkunshito on gastric emptying in patients with NUD,
which supports the data shown in the above basic studies.
Interestingly, in addition to this effect on gastric motility,
rikkunshito also improved GI symptoms in patients with
NUD [52]. To our knowledge, this is the first report in the
English literature that describes rikkunshito as a promising
drug for the improvement of symptoms of FD patients.
Kusunoki et al. [53] showed that rikkunshito may be ben-
eficial for the treatment of FD patients with impaired
gastric accommodation and gastric motility evaluated by
the extracorporeal ultrasonography method. On the other
hand, physical and psychological stress often causes gastric
hypersensitivity to stimulation by mechanical balloon dis-
tension, which is generally well known as a pathogenesis of
FD. Shiratori et al. [54] showed that rikkunshito may
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improve stress-induced gastric hypersensitivity and/or
changes in gastric wall tone by using gastric barostat
method. One report assessed the efficacy of some herbal
medicines under the condition of venipuncture stress.
Rikkunshito and hangeshashinto but not hangekobokuto or
ninjinto reversed the increase in plasma levels of neuro-
peptide Y, a representative neurotransmitter of the sym-
pathetic nervous system of ANS, to the control levels [55].
In addition, administration of rikkunshito decreases the
afferent activity of the gastric vagal nerve, but increased
the efferent activities of the gastric branches of the vagal
nerve [56]. From these findings with the fact that activity of
sympathetic nervous system in the ANS of FD patient was
relatively higher compared to that of the parasympathetic
nervous system [57], the above might be another pharma-
cological action of rikkunshito for the improvement of
dyspeptic symptoms. According to another comparative
human study, rikkunshito but not domperidone also
improves symptoms of patients with FD in parallel with
plasma ghrelin levels [58]. Rikkunshito also has an impact
on delayed gastric emptying in severely handicapped
patients [59] and on the coordination of the gastric myo-
electric activity in post-operative dyspeptic children after
GI surgery [60]. These findings suggest that rikkunshito
improves dyspeptic symptoms mediated by regulating
gastric sensorimotor function or some inflammatory and/or
neuroendocrinal mediators. Oikawa et al. also reported the
efficacy of hangekoubokuto in FD patients. This efficacy is
mediated by a reduction of gas volume in parallel with the
improvement of symptoms of abdominal pain, indigestion,
and constipation [61]. Thus, there are some candidates
among various Japanese traditional medicines for the
treatment of both histological and symptomatic gastritis.
Motility disorders and inflammations of the small
intestine
The physiological function of the small intestine mainly
comprises ingestion and absorption of foods throughout GI
transit. Spontaneous peristaltic contraction is vital for the
performance of these functions. Therefore, a regulated
intestinal motility is important to maintain its integrity and
achieve these functions. However, disorders of intestinal
motility often occur under some pathological conditions
due to surgical operation and abdominal irradiation for
treating some neoplasms, the unfavorable conditions of
which lead to serious symptoms. Therefore, some effective
drugs including Japanese traditional medicines that regu-
late intestinal motility are needed in the clinical field. Apart
from rikkunshito, a variety of reports have documented the
effectiveness of daikenchuto in such cases. Daikenchuto is
composed of Zanthoxyli fructus, Ginseng radix, Zingiberis
siccatum rhizoma, and maltose syrup powder and generally
accelerates intestinal motility in various animal models of
intestinal dysmotility, viz., mouse [62, 63], rat [64–66],
guinea pig [67, 68], rabbit [69], or dog [70, 71]. The
pharmacological functions of this drug are usually medi-
ated by an increase in acetylcholine release through the
vagal nerve, cholinergic neuron, or 5-HT3 and/or 5-HT4
receptors [64–67, 70–72]. Another report showed that a
possible role of daikenchuto in postoperative adhesive
obstruction via transient receptor potential vanilloid type 1
channel [73]. In addition, daikenchuto exhibit anti-inflam-
matory activity in rat intestinal mucosal injuries, mediated
by decreased expressions of interleukin-1 and interferon
(IFN)-c [74] and in bacterial translocation models, medi-
ated by reducing inflammatory reaction and maintaining
intestinal integrity [75]. Further examinations showed that
the main component exerting this pharmacological func-
tion is hydroxy sanshool, one of the chief constituents of
Zanthosyli fructus included in daikenchuto [66, 69–71, 76].
These findings from various basic studies correctively
suggest that daikenchuto may be useful for the treatment of
post-operative adhesive obstructions or ileus.
In clinical studies, a similar action of daikenchuto on
intestinal motility has been reported. Manabe et al. [77]
showed that daikenchuto led to an increase in intestinal
motility in a randomized placebo controlled study in healthy
humans. Another study with human subjects suggested that
the effect of daikenchuto on intestinal transit may be medi-
ated by the releases of motilin and vasoactive intestinal
peptide (VIP) into the plasma through muscarinic receptor 1
[78]. Daikenchuto is reported to improve the stasis of
patients with total gastrectomy and jejunal pouch interposi-
tion [79], decrease the prevalence rate of re-operation asso-
ciated with ileus after abdominal surgery [80], and attenuate
radiation-induced enteritis [81]. Thus, it was concluded that
the pharmacological action of this drug is mainly mediated
by improvement of intestinal motility. Interestingly, daik-
enchuto is also reported to increase human portal blood flow
mediated by an increase in the intestinal blood flow without
an increase in the cardiac output [82, 83]. It is also confirmed
that an increase in intestinal blood flow by daikenchuto is
mainly mediated by calcitonin gene-related peptide (CGRP)
[84]. Thus, Japanese traditional medicines could regulate the
physiological function of the small intestine, particularly,
intestinal motility, although definitive evidence is limited
only to daikenchuto at present.
Colonic motility, secretions, and inflammation-colitis
and irritable bowel syndrome
Colonic transit in cooperation with mucus secretions plays
an important role in the regulation of fecal conditions, such
456 J Gastroenterol (2013) 48:452–462
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as constipation and diarrhea, after ingestion of food intake.
Constipation and diarrhea are usually recognized as the
common complaints but are not associated with severe life-
threatening diseases in the general clinical field. It is also
well known that there seems to be a high prevalence of
patients with these symptoms, including those individual
who have never visited any medical institutions despite
having these unfavorable conditions. In addition to the
efficacy of Japanese traditional medicines for intestinal
contraction, some of these medicines can also regulate
colonic motility and improve fecal conditions and their
related symptoms. In basic studies, daikenchuto has been
found to exhibit prokinetic effects on the total GI tract,
including the stomach, duodenum, jejunum, ileum, and
colon during the fasting state [85]. However, this effect
was attenuated during the fed state when daikenchuto was
administered orally. Conversely, intracolonic administra-
tion of daikenchuto induced a colonic contraction similar to
that during both the fasting and the fed states, and the
related defecation occurred despite the differences in
administration site and timing [85]. Based on these find-
ings, the focal administration of this drug may be optimal
for the treatment of intestinal obstruction, such as postop-
erative ileus. Moreover, daikenchuto improves the opioid-
induced disorders of the colonic motility, which is similar
to that seen by naloxone. As a result, Wood et al. [86]
concluded that daikenchuto may have a beneficial effect on
the restoration of colonic motility in postoperative patients
with opiate analgesic therapy. Human studies revealed that
the prokinetic effect of daikenchuto on colonic motility
was mediated by increase in the levels of plasma motilin,
VIP, and 5-HT [87, 88]. On the other hand, Kono et al. [89]
showed that, in rats, daikenchuto can also increase blood
flow in the colon via CGRP and receptor-activity modify-
ing protein 1. In another human study, increase in the blood
flow by daikenchuto was mediated by increase in the levels
of plasma CGRP and substance P [90].
In a clinical study with healthy volunteers, occurrence of
colonic motility was immediately confirmed by extraso-
matic ultrasonography for 30 min after administration of
daikenchuto into the ascending colon. However, no colonic
contractions were observed in the right colon after
administration of saline solution alone [91]. In patients
hepatectomized by laparotomy, paralytic ileus occasionally
occurs as a complication during the early postoperative
period, which often causes post-resection liver failure due
to hyperammonemia. Daikenchuto can prevent such unfa-
vorable condition by improvement of delayed flatulence
and hyperammonemia [92], and also accelerate the times to
initial flatus and tolerance of regular diet by increasing
bowel movement in patients after colorectal surgery [93].
Thereafter, it has been confirmed that daikenchuto
improves some disorders of the colon such as obstructive
bowel disease [94] or anorectal dysfunction with severe
constipation in children [95, 96], and constipation in
patients with Parkinson’s disease [97]. Based on these
findings, daikenchuto has been recognized as a prokinetic
agent that is effective in the treatment of constipation and
postoperative motility disorders.
Furthermore, daikenchuto exhibits anti-inflammatory
effects. In a representative experimental colitis model
induced by trinitrobenzene sulfonic acid (TNBS), daik-
enchuto ameliorated microvascular dysfunction via the
regulation of endogenous adrenomedullin [98]. Further-
more, daikenchuto inhibits mucosal injuries and adhesion
of the colonic serosa caused by focal inflammation and
decreases cytokine levels of tumor necrosis factor and IFN-
c via the same mechanism [99]. As the pathophysiology of
irritable bowel syndrome (IBS), low grade inflammation of
the intestine is associated with its hypercontractility lead-
ing to clinical diarrhea. Therefore, both regulation of
colonic motility and inflammation are important for the
therapeutic strategy. Intestinal muscle hypercontractility
associated with inflammation in a T cell-mediated model of
enteropathy was ameliorated by daikenchuto, which indi-
cated that this pharmacological function was mediated by
decrease in pro- and anti-inflammatory cytokines [100].
Therefore, the possibility of daikenchuto for treating
patients with IBS was suggested. As another function of
daikenchuto, Inoue et al. [101] reported the regulation
of intestinal fibrosis associated with decreasing expression
of heat shock protein 47 and collagen content in this model.
Radiation-induced enteritis occurs during radiotherapy for
pelvic cancers. This disease often impairs the QOL of the
affected individual. Unfortunately, there is no definite
therapeutic rationale for this disease. However, one case
report states that daikenchuto has the potential to manage
radiation-induced enteritis perhaps owing to its anti-
inflammatory action [81]. In a retrospective observational
clinical study, daikenchuto reduced the duration of long-
tube decompression and saved costs by prevention of
postoperative adhesive small bowel obstruction, which is a
major complication of abdominal surgery [102]. The
comparative study showed that daikenchuto lowered the
inflammatory responses associated with laparoscopic
colorectal resection and shortened the time to first flatus
[103]. Thus, daikenchuto may be useful as a prokinetic
and anti-inflammatory drug under various pathological
conditions.
Further, hangeshashinto has a potent and special effect
on the lower intestinal tract. Through a series of pharma-
cological studies of hangeshashinto for colonic functions,
Kase et al. have accumulated several basic evidences
regarding its anti-diarrheal effects. Firstly, they showed the
dose-dependent effects of this drug via an increase in water
absorption in the colon but not inhibition of colonic transit
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in a castor oil-induced diarrhea model [104, 105]. The
other mechanism(s) of anti-diarrheal effects of hangesha-
shinto was proved by increases in serum corticosterone
levels and fluid secretion. It was also confirmed that a
decrease in prostaglandin E2 contents associated with anti-
diarrheal effects was caused by an inhibition of cycloox-
ygenase type 2. In addition, there are some reports on the
association between hangeshashinto and GI motility regu-
latory peptides (somatostatin, motilin, gastrin, and VIP) or
neuropeptides (5-HT, CGRP, and substance P). Hange-
shashinto increases the plasma levels of somatostatin,
motilin, gastrin, CGRP, and substance P, but did not have
an effect on the levels of 5-HT, mineral balance, or aldo-
sterone [105–110]. Hangeshashinto also improved macro-
scopic injuries and body weight loss in a TNBS-induced
colitis model [111]. Unfortunately, thus far, pharmaceutical
evidence for hangeshashinto might be derived only from
these complicated interactions. However, hangeshashinto
also has the potential to maintain the integrity of the GI
tract, including the improvement of clinical colitis.
Miscellaneous: supportive care during systemic
chemotherapy
In the clinical field, most clinicians often encounter various
patients with general malaise and have trouble treating
these patients in coordination with the severity of their
symptoms. General malaise includes anorexia, headache,
dizziness, nausea, emesis, discomfort, and diarrhea. Fur-
thermore, because the QOL of these patients lowers dras-
tically with the severity of their malaise, clinicians need to
improve their symptoms as soon as possible. In such cases,
kampo medicines are used more frequently than the usual
common drugs as comprehensively alternative medicines,
because it is well known that kampo medicines can affect
the physiological as well as the mental conditions. There-
fore, kampo therapy may be the logically correct strategy
for treatment in patients with numerous general malaise.
However, it is difficult to establish the basic and clinical
evidence for kampo medicines in the treatment of general
malaise. Among various pathological conditions, it is well
known that systemic chemotherapy using anti-cancer drugs
causes symptoms similar to general malaise including
anorexia, emesis, or diarrhea, which sometimes lead to
serious life-threatening conditions. For instance, irinotecan
hydrochloride (CPT-11) is often effectively used to treat
cancers of the lung, colon, or ovarian cancers but can cause
severe diarrhea as an adverse event. There is some evi-
dence that hangeshashinto helps alleviate such adverse
events. Hangeshashinto prevented CPT-11-induced symp-
toms such as diarrhea, anorexia, and body weight loss in
rats, without a loss of its antitumor effects [112, 113]. In
the same model, hangeshashinto led to an increase in water
absorption in the colon, mediated by an inhibition of
prostaglandin E2 synthesis [114]. Another clinical study
confirmed the preventive effect of hangeshashinto toward
CPT-11-induced diarrhea in patients with advanced non-
small-cell lung cancer [115]. We believe that, in the current
literature, there is some evidence supporting the efficacy of
this agent in patients with gastric or colon cancers.
Apart from diarrhea, anorexia is another critical cause
for discontinuation of chemotherapy. Therefore, a candi-
date drug improving anorexia may be useful in such cases.
However, only a limited number of agents that can effec-
tively increase food intake have been established. Some
reports show that rikkunshito can regulate some humoral
factors, including gut regulatory peptides (somatostatin,
gastrin, VIP, or CGRP) [110, 116], and improve stress-
associated diseases by decreasing the levels of adrenocor-
ticotropic hormone or cortisol [117]. Considering these
effects of rikkunshito and its efficacy in patients with
FGIDs, rikkunshito could serve as candidate supporting
drug for improving systemic general malaise. Recently, it
has been proved that rikkunshito can increase food intake
and improve anorexia under unfavorable condition by
increasing in plasma ghrelin levels. First, Takeda et al. [12]
showed that rikkunshito suppresses cisplatin-induced
anorexia in rats via 5-HT2 receptor antagonism. Thereafter,
Yakabi et al. [13, 118] showed that rikkunshito led to
improvement for the reduced secretion of ghrelin in the
hypothalamus and resulted in the improvement of cisplatin-
induced anorexia. Another report states that a component
of rikkunshito (10-Gingerol) improves cisplatin-induced
anorexia by inhibiting acylated ghrelin degradation [119].
Basic research shows that rikkunshito suppresses anorexia,
emesis, or decrease in QOL under the condition of systemic
chemotherapy with cisplatin etc. by increasing the secre-
tion of plasma ghrelin [120, 121]. Thus, rikkunshito may be
useful for supportive care during chemotherapy. Therefore,
some kampo medicines seem to be more and more useful
for treatment for general malaises in the future.
Concluding remarks
The Japanese medical treatment kampo is frequently pre-
scribed for patients with numerous GI tract disorders
associated with various symptoms, including general mal-
aise. This treatment should be recommended theoretically,
because it combines modern Western and traditional Asian
medical practices. However, kampo medicines are not used
widely worldwide and are considered ‘‘complementary’’
medicines and not ‘‘mainstream’’. This is because the
mechanism of their pharmacological actions is not so clear
and because of the lack of established kampo educational
458 J Gastroenterol (2013) 48:452–462
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system in Japan. It is suggested that kampo medicines must
be developed to the evidenced-based medicine from the
empirical-based medicine in the near future by making
known their much more benefits to the whole world.
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